Apogee Therapeutics, Inc. Operating Lease, Expense
Apogee Therapeutics, Inc. (APGE) reported Operating Lease, Expense of $1.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-10
- Apogee Therapeutics, Inc. operating lease, expense for the quarter ending 2026-06-30 was $1.10M, a 0.00% change year-over-year.
- Apogee Therapeutics, Inc. operating lease, expense for the quarter ending 2026-03-31 was $1.10M, a 0.00% change year-over-year.
- Apogee Therapeutics, Inc. operating lease, expense for the quarter ending 2025-12-31 was $1.10M, a 10.00% increase year-over-year.
- Apogee Therapeutics, Inc. operating lease, expense for the quarter ending 2025-09-30 was $1.10M, a 83.33% increase year-over-year.
- Apogee Therapeutics, Inc. operating lease, expense for fiscal 2025 was $4.40M, a 91.30% increase from fiscal 2024.
- Apogee Therapeutics, Inc. operating lease, expense for fiscal 2024 was $2.30M, a 2200.00% increase from fiscal 2023.
- Apogee Therapeutics, Inc. operating lease, expense for fiscal 2023 was $100.00K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 3 month as first filed | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month | Operating Lease, Expense 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.10M 10-Q · filed 2026-08-10 | $2.20M 10-Q · filed 2026-08-10 | $3.30M derived: sum of 3 quarters · filed 2026-08-10 | $4.40M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2026-03-31 | $1.10M 10-Q · filed 2026-05-11 | $2.20M derived: sum of 2 quarters · filed 2026-05-11 | $3.30M derived: sum of 3 quarters · filed 2026-05-11 | $4.40M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.20M derived: sum of 2 quarters · filed 2026-03-02 | $3.30M derived: sum of 3 quarters · filed 2026-08-10 | $4.40M 10-K · filed 2026-03-02 | ||
| 2025-09-30 | $1.10M 10-Q · filed 2025-11-10 | $2.20M derived: sum of 2 quarters · filed 2026-08-10 | $3.30M 10-Q · filed 2025-11-10 | $4.30M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-06-30 | $1.10M 10-Q · filed 2026-08-10 | $2.20M 10-Q · filed 2026-08-10 | $3.20M derived: sum of 3 quarters · filed 2026-08-10 | $3.80M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-03-31 | $1.10M 10-Q · filed 2026-05-11 | $2.10M derived: sum of 2 quarters · filed 2026-05-11 | $2.70M derived: sum of 3 quarters · filed 2026-05-11 | $3.10M derived: sum of 4 quarters · filed 2026-05-11 | ||
| 2024-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.60M derived: sum of 2 quarters · filed 2026-03-02 | $2.00M derived: sum of 3 quarters · filed 2026-03-02 | $2.30M 10-K · filed 2026-03-02 | ||
| 2024-09-30 | $600.00K 10-Q · filed 2025-11-10 | $1.00M derived: sum of 2 quarters · filed 2025-11-10 | $1.30M 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | $400.00K 10-Q · filed 2025-08-11 | $700.00K 10-Q · filed 2025-08-11 | ||||
| 2024-03-31 | $300.00K 10-Q · filed 2025-05-12 | $266.00K 10-Q · filed 2024-05-13 | ||||
| 2023-12-31 | $100.00K 10-K · filed 2026-03-02 | $87.00K 10-K · filed 2024-03-05 |